N+NDGD / SCOREStudy & references

NEPHROLOGY · CLINICAL CALCULATOR

NDGD score

Assess non-diabetic glomerular disease in patients with T2DM and nephrotic-range proteinuria.

Research model

Developed and evaluated in 289 patients who underwent kidney biopsy. External validation is required before routine clinical use.

01

Clinical context

Type 2 diabetes with native kidneys (no kidney transplant)
Are any of the following features present?
  • Signs of systemic disease
  • Accelerated hypertension
  • A rapid decline in eGFR of >30% over weeks to months
Nephrotic-range proteinuria

Urine protein ≥3.5 g/day or UPCR ≥3 g/gCr, as defined in the study.

If any feature is present, consider a diagnostic work-up, including kidney biopsy, without calculating the NDGD score.

02

Score inputs

0 / 7
years

≥70 years → +4 points

years

≤5 years → +2.5 points

g/dL

≥12 g/dL → +1.5 points

mL/min/1.73 m²

45–<60 → +1.5 · ≥60 → +3
Use the 2021 CKD-EPI creatinine equation.

History of hypertension —

Before the onset of nephrotic-range proteinuria.

RAS blockade prescribed solely for its antiproteinuric effect does not count as a history of hypertension.

Diabetic retinopathy —

Based on an ophthalmologist’s assessment.

Urine sediment —

Glomerular hematuria contributes 6.5 points only. Do not add the additional hematuria point.

Diagnostic performance

Metrics automatically match the calculated score threshold.

Complete all score inputs to view the reported metrics.

Sensitivity—
Specificity—
PPV—
NPV—
These values describe the biopsy cohort, not an individual probability at an exact score.

PPV and NPV depend on disease prevalence. NDGD was present in 142/289 patients (49.1%), including NDGD with concomitant DN.

REFERENCE

Tirasattayapitak S, Jaturapisanukul S, et al. Clinical Predictors of Non-Diabetic Glomerular Disease in Type 2 Diabetic Patients With Nephrotic-Range Proteinuria. Nephrology. 2026;31:e70275. doi:10.1111/nep.70275 ↗